Latest Healthcare News

Page 8 of 197
Atomo Diagnostics has signed an MOU with Innovation Scientific to develop a fourth-generation HIV rapid test using its Galileo cassette. The project could add a new product to Atomo’s pipeline, but regulatory approval, clinical work and definitive commercial agreements remain outstanding.
Ada Torres
Ada Torres
29 Oct 2026
Integral Diagnostics has opened FY27 below expectations, with radiologist and sonographer shortages limiting revenue growth and pushing labour costs ahead of sales. The company expects FY27 revenue growth of 4% to 6% and a full-year operating EBITDA margin of 19.5% to 20.5%, with improvement weighted to the second half.
Ada Torres
Ada Torres
29 Oct 2026
Saluda Medical delivered a strong operational start to FY27, with US implants up 55% and quarterly revenue rising 26% to US$23.1 million. But the medical device company ended September with US$73.6 million in cash, US$100 million of secured debt drawn and estimated funding for just 2.3 quarters at the quarter’s cash-use rate.
Ada Torres
Ada Torres
29 Oct 2026
PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.
Ada Torres
Ada Torres
29 Oct 2026
Alcidion has started FY27 with contracted revenue up 38% to $50.0 million, while a major UK expansion and new patient administration product widen its growth case. The company has also reaffirmed that FY27 revenue and underlying EBITDA will exceed FY26, but its capital plan now has several competing demands.
Victor Sage
Victor Sage
29 Oct 2026
PainChek is concentrating its commercial effort on residential aged care after signing new US and UK business, including an 808-licence Sabra expansion and an approximately 1,800-licence Hallmark contract. Revenue and retention improved, but activated ARR growth slowed to 1.2% for the quarter and cash covered an estimated 2.5 quarters of historical operating outflows.
Victor Sage
Victor Sage
28 Oct 2026
Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.
Ada Torres
Ada Torres
28 Oct 2026
Dexus has forecast lower FY27 earnings while refocusing its business on office, industrial, retail and selected alternatives. The ASX-listed real estate group is also targeting more than A$2 billion of capital release, but remains exposed to infrastructure fund liquidity issues and the unresolved APAC appeal.
Eva Park
Eva Park
28 Oct 2026
Thrive Tribe Technologies has made progress on its defence and veteran software ambitions, but ended September with just A$20,000 in cash after a A$573,000 operating outflow. Its proposed A$2 million placement remains uncommitted and requires shareholder approval in November.
Sophie Babbage
Sophie Babbage
28 Oct 2026
Adheris Health delivered a stronger first quarter on revenue, margins and its CY27 sales pipeline, but ended September with US$3.5 million in cash after a US$3.1 million operating outflow. The company also disclosed the impending loss of a major pharmacy partner and a US$2.3 million-plus legal claim.
Ada Torres
Ada Torres
28 Oct 2026
4DMedical reported a record first quarter, with scan volumes up 61% to 119,672 and unaudited operating revenue rising 66% to $2.3 million. New contracts across the US, Germany and Australia broaden the commercial story, while $242.8 million in cash gives the company room to keep investing.
Victor Sage
Victor Sage
28 Oct 2026
Epiminder says its $65.1 million cash balance can fund the DETECT study and next-generation Minder device into 2028, despite a higher quarterly operating outflow. The company also paid $3.5 million to major shareholder Cochlear for research and development during the quarter.
Ada Torres
Ada Torres
28 Oct 2026

Browse the archive

Full archive